Nexcelom Maintains Delivery of Products and Services
March 30, 2020
Dear Customers and Colleagues:
The global COVID-19 pandemic has not only posed unprecedented health care challenges but also impacted our way of life and work. I am writing to assure you that we at Nexcelom Bioscience are keeping a constant vigil to prepare for uncertainty and reduce the impact on your work. Currently, Nexcelom continues to maintain normal global operations while adhering to the orders and guidelines issued by governmental and public health authorities. Our first priorities are the health and safety of our employees and our ability to provide uninterrupted service to our customers.
At Nexcelom Bioscience, we are able to respond to your incoming requests for products and services. We are able to continue to manufacture and deliver products to our customers, while working diligently to avoid future disruption to our supply chain and logistic operations.
In addition, though mostly working from home, our Customer Support Team and Field Application Scientists are available during the normal operating hours to assist you with any product or technical needs that you may have. We are also closely coordinating with our distributor partners to ensure that their inventory and operations are fully supported.
At this time of war against the coronavirus, I am proud that we are a member of the crucial industry of life sciences, biomedical research, and discovery and development of therapies and treatments of diseases include COVID-19. We are here to support our customers and colleagues as we always have been and hope you experience minimal disruption in your research and development. Please feel free to contact us with any questions using the contact information at www.nexcelom.com/training-and-support. We will provide further updates here if COVID-19 does begin to impact our business in ways that affects our delivery of products and services.
On behalf of my colleagues at Nexcelom, I wish all of you and your families to stay safe and healthy.
Peter Y. Li, PhD
President & CEO